NO20075344L - Metforminbaserte fremgangsmater og utforminger for behandling av kronisk forstoppelse - Google Patents

Metforminbaserte fremgangsmater og utforminger for behandling av kronisk forstoppelse

Info

Publication number
NO20075344L
NO20075344L NO20075344A NO20075344A NO20075344L NO 20075344 L NO20075344 L NO 20075344L NO 20075344 A NO20075344 A NO 20075344A NO 20075344 A NO20075344 A NO 20075344A NO 20075344 L NO20075344 L NO 20075344L
Authority
NO
Norway
Prior art keywords
metformin
treatment
designs
chronic constipation
methods
Prior art date
Application number
NO20075344A
Other languages
English (en)
Norwegian (no)
Inventor
John Devane
Original Assignee
Agi Therapeutics Res Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Agi Therapeutics Res Ltd filed Critical Agi Therapeutics Res Ltd
Publication of NO20075344L publication Critical patent/NO20075344L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A61K9/2846—Poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/10—Laxatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
NO20075344A 2005-03-18 2007-10-18 Metforminbaserte fremgangsmater og utforminger for behandling av kronisk forstoppelse NO20075344L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US66292005P 2005-03-18 2005-03-18
PCT/IB2006/002233 WO2007007189A2 (en) 2005-03-18 2006-03-16 Metformin methods and formulations for treating chronic constipation

Publications (1)

Publication Number Publication Date
NO20075344L true NO20075344L (no) 2007-10-18

Family

ID=37637555

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20075344A NO20075344L (no) 2005-03-18 2007-10-18 Metforminbaserte fremgangsmater og utforminger for behandling av kronisk forstoppelse

Country Status (10)

Country Link
US (1) US20060222709A1 (enExample)
EP (1) EP1865939A2 (enExample)
JP (1) JP2008533127A (enExample)
AU (1) AU2006268003A1 (enExample)
CA (1) CA2599531A1 (enExample)
IL (1) IL185652A0 (enExample)
MX (1) MX2007011174A (enExample)
NO (1) NO20075344L (enExample)
WO (1) WO2007007189A2 (enExample)
ZA (1) ZA200707325B (enExample)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2367554A4 (en) * 2008-11-26 2020-03-25 Satiogen Pharmaceuticals, Inc. Bile acid reflux inhibitor for the treatment of obesity and diabetes
EP4137137A1 (en) 2010-05-26 2023-02-22 Satiogen Pharmaceuticals, Inc. Bile acid recycling inhibitors and satiogens for treatment of diabetes, obesity, and inflammatory gastrointestinal conditions
WO2012094636A2 (en) 2011-01-07 2012-07-12 Elcelyx Therapeutics, Inc. Chemosensory receptor ligand-based therapies
US9211263B2 (en) 2012-01-06 2015-12-15 Elcelyx Therapeutics, Inc. Compositions and methods of treating metabolic disorders
US9480663B2 (en) 2011-01-07 2016-11-01 Elcelyx Therapeutics, Inc. Biguanide compositions and methods of treating metabolic disorders
US11759441B2 (en) * 2011-01-07 2023-09-19 Anji Pharmaceuticals Inc. Biguanide compositions and methods of treating metabolic disorders
US11974971B2 (en) * 2011-01-07 2024-05-07 Anji Pharmaceuticals Inc. Compositions and methods for treating metabolic disorders
US8796338B2 (en) 2011-01-07 2014-08-05 Elcelyx Therapeutics, Inc Biguanide compositions and methods of treating metabolic disorders
US9572784B2 (en) 2011-01-07 2017-02-21 Elcelyx Therapeutics, Inc. Compositions comprising statins, biguanides and further agents for reducing cardiometabolic risk
EP2599789A1 (en) * 2011-12-01 2013-06-05 Bergen Teknologioverføring AS Marker and method for diagnosing diarrhea syndrome
CN104349773A (zh) * 2012-01-06 2015-02-11 埃尔舍利克斯治疗公司 用于治疗代谢性病症的组合物和方法
BR112014016808B1 (pt) * 2012-01-06 2022-01-11 Anji Pharma (Us) Llc Uso de um composto de biguanida para a fabricação de um medicamento para baixar os níveis de glicose no sangue e para o tratamento de um distúrbio do metabolismo de glicose
AU2013290100A1 (en) * 2012-07-11 2015-01-29 Elcelyx Therapeutics, Inc. Compositions comprising statins, biguanides and further agents for reducing cardiometabolic risk
BR112015004165A2 (pt) * 2012-08-29 2017-07-04 Salix Pharmaceuticals Inc métodos e composições laxantes para o tratamento de constipação e condições e doenças gastrointestinais relacionadas
EP2941245B1 (en) * 2013-01-05 2024-06-26 Anji Pharmaceuticals Inc. Delayed-release composition comprising biguanide
CN104434846A (zh) * 2014-11-17 2015-03-25 中国药科大学 盐酸二甲双胍肠溶缓释微丸及其制备方法
TW201938147A (zh) * 2017-12-18 2019-10-01 德商拜耳廠股份有限公司 阿卡波糖與甲福明之固定劑量組合錠劑配製物及其製法
EP4045520A1 (en) 2019-10-16 2022-08-24 Bayer Aktiengesellschaft Methods for the improved formation of acarbose
JP2025535564A (ja) 2022-11-07 2025-10-24 リジュベネイト バイオメッド エヌブイ メトホルミンミニ錠剤
CN121846068A (zh) * 2023-08-22 2026-04-14 雅研(天津)生物医药科技中心(有限合伙) 盐酸二甲双胍肠溶制剂

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999047128A1 (en) * 1998-03-19 1999-09-23 Bristol-Myers Squibb Company Biphasic controlled release delivery system for high solubility pharmaceuticals and method
WO2000028989A1 (en) * 1998-11-12 2000-05-25 Smithkline Beecham P.L.C. Pharmaceutical composition for modified release of an insulin sensitiser and another antidiabetic agent
US6676966B1 (en) * 2000-05-09 2004-01-13 Intellipharmaceutics Corp. Extended release metformin hydrochloride formulations
US6790459B1 (en) * 2000-11-03 2004-09-14 Andrx Labs, Llc Methods for treating diabetes via administration of controlled release metformin
US7985422B2 (en) * 2002-08-05 2011-07-26 Torrent Pharmaceuticals Limited Dosage form
US20060045865A1 (en) * 2004-08-27 2006-03-02 Spherics, Inc. Controlled regional oral delivery

Also Published As

Publication number Publication date
US20060222709A1 (en) 2006-10-05
EP1865939A2 (en) 2007-12-19
JP2008533127A (ja) 2008-08-21
CA2599531A1 (en) 2007-01-18
ZA200707325B (en) 2009-03-25
WO2007007189A2 (en) 2007-01-18
AU2006268003A1 (en) 2007-01-18
MX2007011174A (es) 2008-02-11
IL185652A0 (en) 2008-01-06
WO2007007189A3 (en) 2007-04-26

Similar Documents

Publication Publication Date Title
NO20074509L (no) Kombinasjon av organiske forbindelser
MX2007011174A (es) Metodos y formulaciones de metformina para tratar constipacion cronica.
NO20025601D0 (no) Arylmetylaminderivater for anvendelse som tryptaseinhibitorer
WO2008050329A3 (en) Novel sirnas and methods of use thereof
NZ572049A (en) Method for treatment of constipation-predominant irritable bowel syndrome
EA201100266A1 (ru) Диокса-бицикло[3.2.1]октан-2,3,4-триольные производные
GT200500137A (es) Derivados de pirrolotriazina utiles para tratar trastornos hiper-proliferativos y enfermedades asociadas con angiogenesis.
NO20065847L (no) Difenylimidazopyrimidiner og -imidazolaminer som inhibitorer av B-sekretase
WO2006012642A3 (en) Pyrrole derivatives as pharmaceutical agents
NO20076319L (no) Farmasoytiske sammensetninger av et neuroaktivt steroid og anvendelse derav
TW200745124A (en) Azepinoindole derivatives as pharmaceutical agents
DK1296972T3 (da) Arylmethylamin-derivater til anvendelse som tryptaseinhibitorer
NO20070597L (no) Medikamtenter for a behandle kronisk respiratorisk sykdom.
DK1845994T3 (da) Kombination af methylxanthinforbindelser og steroider til at behandle kroniske luftvejssygdomme
WO2008079159A3 (en) Chemicals, compositions, and methods for treatment and prevention of orthopoxvirus infections and associated diseases
BRPI0519124A2 (pt) composto, mÉtodo para tratar, prevenir ou melhorar obesidade e doenÇas relacionadas e/ou sintomas das mesmas, composiÇço farmacÊutica, uso de composto, e, combinaÇço
WO2011005811A8 (en) Combination therapy for the treatment of diabetes
WO2007128086A3 (en) Novel viral replication inhibitor
WO2007046868A3 (en) Thiazolidine derivatives and their uses as therapeutic agents
NO20075393L (no) Akarbosebaserte fremgangsmater og utforminger for behandling av kronisk forstoppelse
CY1116601T1 (el) Φαρμακευτικη συνθεση που βασιζεται σε ηπατοπροστατευτικο παραγοντα και πρεβιοτικο, η παραγωγη και χρηση της
MX2009005798A (es) Recuperacion de apoplejia.
WO2007046867A3 (en) Piperidine derivatives and their uses as therapeutic agents
WO2008048648A3 (en) Cb1-modulating compounds and their use
WO2006020680A3 (en) Heterocyclic compounds as pharmaceutical agents

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application